What should I avoid while taking Bosentan 62.5mg tablets?

Take with or without food. The absorption is unaffected by food. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Bosentan 62.5mg tablets?

Bosentan 62.5mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Bosentan 62.5mg tablets?

Bosentan 62.5mg tablets is the generic name. It is available under brand names including: Bosentan 62.5mg tablets, Bosentan 62.5mg tablets, Bosentan 62.5mg tablets, Bosentan 62.5mg tablets, Bosentan 62.5mg tablets and 3 more. (Source: NHS dm+d — Actual Medicinal Products)

Bosentan 62.5mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

62.5mg

Oral

Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals.

Active ingredients:

Bosentan

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC C02KX01

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Bosentan

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Bosentan

Source: MHRA Products DatabaseOGL 3.0

Updated 16 Jan 2026

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Bosentan

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Bosentan

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

8 branded products available

8 products

Possibly available on the UK marketDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Bosentan on the MHRA register

Bosentan 62.5mg tablets

Viatris UK Healthcare Ltd

Bosentan 62.5mg tablets

Accord-UK Ltd

Bosentan 62.5mg tablets

Cipla EU Ltd

Stayveer 62.5mg tablets

Advanz Pharma

Discontinued

Tracleer 62.5mg tablets

Janssen-Cilag Ltd

Discontinued

Bosentan 62.5mg tablets

Zentiva Pharma UK Ltd

Discontinued

Bosentan 62.5mg tablets

Milpharm Ltd

Discontinued

Bosentan 62.5mg tablets

Dr Reddy's Laboratories (UK) Ltd

Discontinued

Source: NHS dm+dOGL 3.0

Updated 1 Mar 2026

Daily dose

WHO defined daily dose (DDD)

250 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

Injection

45mg

Same therapeutic group

Sotatercept 60mg powder and solvent for solution for injection vials

Injection

60mg

Same therapeutic group

Macitentan 2.5mg dispersible tablets sugar free

Tablet

2.5mg

Same therapeutic group

Ambrisentan 2.5mg tablets

Tablet

2.5mg

Same therapeutic group

Riociguat 500microgram tablets

Tablet

Same therapeutic group

Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Loading prescribing data...

Guidelines from the National Institute for Health and Care Excellence

NICE clinical guidance(2)

Digital ulcers: sildenafil (ESUOM42)

ESUOM42

Evidence summary

Updated Mar 2015

Idiopathic pulmonary fibrosis in adults: diagnosis and management (CG163)

CG163

Clinical guideline

Updated May 2017

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & safety information

Official UK regulator monitoring and safety alerts

MHRA drug safety updates

UK regulator alerts and supply notices

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).

Codes for healthcare professionals and prescribing systems

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

39734011000001108

dm+d ID

39734011000001108

VTM (Virtual Therapeutic Moiety)

774891004

VMP (Virtual Medicinal Product)

39734011000001108

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

C02KX01

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Academic studies and reviews for this medicine's active substance

Showing the 50 most relevant studies.

Reviews & meta-analyses: 11 · Randomised trials: 16 · 1994–2026

Sort

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.

N. Galiè, Lewis J. Rubin, M. Hoeper, et al.

Lancet, 2008

Randomised trial

Cited by 924

BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.

T. King, K. Brown, G. Raghu, et al.

American journal of respiratory and critical care medicine, 2011

Randomised trial

Cited by 660

Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.

X. Jaïs, A. D’Armini, P. Jansa, et al.

Journal of the American College of Cardiology, 2008

Randomised trial

Cited by 573

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

Marco Matucci-Cerinic, Christopher P. Denton, Daniel E. Furst, et al.

Annals of the Rheumatic Diseases, 2010

Randomised trial

Cited by 463

BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.

T. King, J. Behr, K. Brown, et al.

American journal of respiratory and critical care medicine, 2008

Randomised trial

Cited by 361

Efficacy and safety of bosentan-related therapy in neonates with persistent pulmonary hypertension of the newborn: a systematic review and meta-analysis

Guanghong Li, Xiaoqun Du, Weibin Luo, et al.

Frontiers in Pediatrics, 2026

Systematic review

Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial.

R. Baughman, D. Culver, F. Cordova, et al.

Chest, 2014

Randomised trial

Cited by 142

Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial

Mark J Schuuring, J. C. Vis, A. V. van Dijk, et al.

European Journal of Heart Failure, 2013

Randomised trial

Cited by 135

Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial.

R. Steinhorn, J. Fineman, Andjela Kusic-Pajic, et al.

The Journal of pediatrics, 2016

Randomised trial

Cited by 79

Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review

R. You, Xinyu Qian, Weijing Tang, et al.

Canadian Respiratory Journal, 2018

Systematic review

Cited by 8

Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

5 found

Half-life

5 hours

Mechanism

Endothelin-1 (ET-1) is a neurohormone, the effects of which are mediated by bind…

Food interactions

1 warning

Human targets

2 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

50%

Absolute bioavailability is approximately 50% and food does not affect absorption.

Half-life

5 hours

Terminal elimination half-life is about 5 hours in healthy adult subjects.

Protein binding

98%

Greater than 98% to plasma proteins, mainly albumin.

Volume of distribution

18 L

* 18 L

Metabolism

10 to 20%

Bosentan is metabolized in the liver by the cytochrome P450 enzymes CYP2C9 and CYP3A4 (and possibly CYP2C19), producing three metabolites, one…

Elimination

Bosentan is eliminated by biliary excretion following metabolism in the liver.

Clearance

4 L/h

* 4 L/h [patients with pulmonary arterial hypertension]

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.

Properties:

solid

Avg. mass: 551.61 Da

View FDA drug label

DrugBank indication

Used in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms).

Also known as(46)

4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide

bosentán

Bosentan

bosentan anhydrous

bosentanum

p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide

Endothelin receptor non-selective type

ET-B

Molecular properties(19)

Drug interactions(1262)

Known interactions with other medicines. Always consult a healthcare professional.

Cyclosporine

Moderate

DB00091

The serum concentration of Bosentan can be increased when it is combined with Cyclosporine.

Check this interaction

Glycochenodeoxycholic Acid

Moderate

DB02123

Bosentan may decrease the excretion rate of Glycochenodeoxycholic Acid which could result in a higher serum level.

Check this interaction

Fluvoxamine

Moderate

DB00176

Bosentan may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.

Check this interaction

Glimepiride

Moderate

DB00222

Bosentan may decrease the excretion rate of Glimepiride which could result in a higher serum level.

Check this interaction

Isradipine

Moderate

DB00270

Bosentan may decrease the excretion rate of Isradipine which could result in a higher serum level.

Check this interaction

Flucloxacillin

Moderate

DB00301

Bosentan may decrease the excretion rate of Flucloxacillin which could result in a higher serum level.

Check this interaction

Indomethacin

Moderate

DB00328

Bosentan may decrease the excretion rate of Indomethacin which could result in a higher serum level.

Check this interaction

Atenolol

Moderate

DB00335

Bosentan may decrease the excretion rate of Atenolol which could result in a higher serum level.

Check this interaction

Rosiglitazone

Moderate

DB00412

Bosentan may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.

Check this interaction

Spironolactone

Moderate

DB00421

Spironolactone may increase the hypotensive activities of Bosentan.

Check this interaction

Cerivastatin

Moderate

DB00439

Bosentan may decrease the excretion rate of Cerivastatin which could result in a higher serum level.

Check this interaction

Loratadine

Moderate

DB00455

Bosentan may decrease the excretion rate of Loratadine which could result in a higher serum level.

Check this interaction

Atropine

Moderate

DB00572

Bosentan may decrease the excretion rate of Atropine which could result in a higher serum level.

Check this interaction

Diclofenac

Moderate

DB00586

Bosentan may decrease the excretion rate of Diclofenac which could result in a higher serum level.

Check this interaction

Losartan

Moderate

DB00678

The metabolism of Losartan can be increased when combined with Bosentan.

Check this interaction

Fluorescein

Moderate

DB00693

Bosentan may decrease the excretion rate of Fluorescein which could result in a higher serum level.

Check this interaction

Nitrofurantoin

Moderate

DB00698

Bosentan may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.

Check this interaction

Naproxen

Moderate

DB00788

Bosentan may decrease the excretion rate of Naproxen which could result in a higher serum level.

Check this interaction

Disulfiram

Moderate

DB00822

Bosentan may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Cefaclor

Moderate

DB00833

Bosentan may decrease the excretion rate of Cefaclor which could result in a higher serum level.

Check this interaction

Tinidazole

Moderate

DB00911

Bosentan may decrease the excretion rate of Tinidazole which could result in a higher serum level.

Check this interaction

Repaglinide

Moderate

DB00912

Bosentan may decrease the excretion rate of Repaglinide which could result in a higher serum level.

Check this interaction

Telmisartan

Moderate

DB00966

Bosentan may decrease the excretion rate of Telmisartan which could result in a higher serum level.

Check this interaction

Ezetimibe

Moderate

DB00973

Bosentan may decrease the excretion rate of Ezetimibe which could result in a higher serum level.

Check this interaction

Dipyridamole

Moderate

DB00975

Bosentan may decrease the excretion rate of Dipyridamole which could result in a higher serum level.

Check this interaction

Sulfamethoxazole

Moderate

DB01015

Bosentan may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.

Check this interaction

Fenofibrate

Moderate

DB01039

Bosentan may decrease the excretion rate of Fenofibrate which could result in a higher serum level.

Check this interaction

Nitrendipine

Moderate

DB01054

Bosentan may decrease the excretion rate of Nitrendipine which could result in a higher serum level.

Check this interaction

Glipizide

Moderate

DB01067

Bosentan may decrease the excretion rate of Glipizide which could result in a higher serum level.

Check this interaction

Sulfinpyrazone

Moderate

DB01138

Bosentan may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.

Check this interaction

Ofloxacin

Moderate

DB01165

Bosentan may decrease the excretion rate of Ofloxacin which could result in a higher serum level.

Check this interaction

Taurocholic acid

Moderate

DB04348

Bosentan may decrease the excretion rate of Taurocholic acid which could result in a higher serum level.

Check this interaction

Prasterone sulfate

Moderate

DB05804

Bosentan may decrease the excretion rate of Prasterone sulfate which could result in a higher serum level.

Check this interaction

Indocyanine green acid form

Moderate

DB09374

Bosentan may decrease the excretion rate of Indocyanine green acid form which could result in a higher serum level.

Check this interaction

Benzbromarone

Moderate

DB12319

Bosentan may decrease the excretion rate of Benzbromarone which could result in a higher serum level.

Check this interaction

Pilsicainide

Moderate

DB12712

Bosentan may decrease the excretion rate of Pilsicainide which could result in a higher serum level.

Check this interaction

Dihydroergocristine

Moderate

DB13345

Bosentan may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.

Check this interaction

Glycyrrhizic acid

Moderate

DB13751

Bosentan may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.

Check this interaction

Nifedipine

Moderate

DB01115

Bosentan may decrease the excretion rate of Nifedipine which could result in a higher serum level.

Check this interaction

Budesonide

Moderate

DB01222

Bosentan may decrease the excretion rate of Budesonide which could result in a higher serum level.

Check this interaction

Belantamab mafodotin

Moderate

DB15719

Bosentan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.

Check this interaction

Aripiprazole

Moderate

DB01238

The metabolism of Aripiprazole can be increased when combined with Bosentan.

Check this interaction

Aripiprazole lauroxil

Moderate

DB14185

The metabolism of Aripiprazole lauroxil can be increased when combined with Bosentan.

Check this interaction

Alfuzosin

Moderate

DB00346

Alfuzosin may increase the hypotensive activities of Bosentan.

Check this interaction

Amifostine

Moderate

DB01143

Bosentan may increase the hypotensive activities of Amifostine.

Check this interaction

Diazoxide

Moderate

DB01119

Diazoxide may increase the hypotensive activities of Bosentan.

Check this interaction

Methylphenidate

Moderate

DB00422

Methylphenidate may decrease the antihypertensive activities of Bosentan.

Check this interaction

Dexmethylphenidate

Moderate

DB06701

Dexmethylphenidate may decrease the antihypertensive activities of Bosentan.

Check this interaction

Obinutuzumab

Moderate

DB08935

Bosentan may increase the hypotensive activities of Obinutuzumab.

Check this interaction

Pentoxifylline

Moderate

DB00806

Pentoxifylline may increase the hypotensive activities of Bosentan.

Check this interaction

Showing 50 of 1262 interactions

Food & lifestyle interactions

Advice

Take with or without food. The absorption is unaffected by food.

Toxicity & overdose

Bosentan has been given as a single dose of up to 2400 mg in normal volunteers, or up to 2000 mg/day for 2 months in patients, without any major clinical consequences. The most common side effect was headache of mild to moderate intensity. In the cyclosporine A interaction study, in which doses of 500 and 1000 mg b.i.d. of bosentan were given concomitantly with cyclosporine A, trough plasma concentrations of bosentan increased 30-fold, resulting in severe headache, nausea, and vomiting, but no serious adverse events.

Mild decreases in blood pressure and increases in heart rate were observed. There is no specific experience of overdosage with bosentan beyond the doses described above. Massive overdosage may result in pronounced hypotension requiring active cardiovascular support.

How it works

Mechanism of action

Endothelin-1 (ET-1) is a neurohormone, the effects of which are mediated by binding to ET_A and ET_B receptors in the endothelium and vascular smooth muscle. It displays a slightly higher affinity towards ET_A receptors than ET_B receptors. ET-1 concentrations are elevated in plasma and lung tissue of patients with pulmonary arterial hypertension, suggesting a pathogenic role for ET-1 in this disease. Bosentan is a specific and competitive antagonist at endothelin receptor types ET_A and ET_B.

Pharmacodynamics

Bosentan belongs to a class of drugs known as endothelin receptor antagonists (ERAs). Patients with PAH have elevated levels of endothelin, a potent blood vessel constrictor, in their plasma and lung tissue. Bosentan blocks the binding of endothelin to its receptors, thereby negating endothelin's deleterious effects.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Absolute bioavailability is approximately 50% and food does not affect absorption.

Half-life

Terminal elimination half-life is about 5 hours in healthy adult subjects.

Protein binding

Greater than 98% to plasma proteins, mainly albumin.

Volume of distribution

* 18 L

Metabolism

Bosentan is metabolized in the liver by the cytochrome P450 enzymes CYP2C9 and CYP3A4 (and possibly CYP2C19), producing three metabolites, one of which, Ro 48-5033, is pharmacologically active and may contribute 10 to 20% to the total activity of the parent compound.

Route of elimination

Bosentan is eliminated by biliary excretion following metabolism in the liver.

Clearance

* 4 L/h [patients with pulmonary arterial hypertension]

Drug targets(2)

Proteins and enzymes this drug interacts with in the body

Endothelin receptor type B

BE0000043

EDNRB

antagonist

Specific functionendothelin receptor activity

Cellular location

Cell membrane

General function & pharmacology

Non-specific receptor for endothelin 1, 2, and 3. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system

Endothelin-1 receptor

BE0000521

EDNRA

antagonist

Specific functionendothelin receptor activity

Cellular location

Cell membrane

General function & pharmacology

Receptor for endothelin-1. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of binding affinities for ET-A is: ET1 > ET2 >> ET3

Metabolizing enzymes(2)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP3A4Cytochrome P450 3A4

substrate

inducer

CYP2C9Cytochrome P450 2C9

substrate

inducer

Transporters(1)

Proteins that transport this drug across cell membranes

Bile salt export pump

BE0000703

ABCB11

inhibitor

Specific functionABC-type bile acid transporter activity

Cellular location

Apical cell membrane

General function & pharmacology

Catalyzes the transport of the major hydrophobic bile salts, such as taurine and glycine-conjugated cholic acid across the canalicular membrane of hepatocytes in an ATP-dependent manner, therefore participates in hepatic bile acid homeostasis and consequently to lipid homeostasis through regulation of biliary lipid secretion in a bile salts dependent manner .
PMID:15791618 PMID:16332456 PMID:18985798 PMID:19228692 PMID:20010382 PMID:20398791 PMID:22262466 PMID:24711118 PMID:29507376 PMID:32203132

Transports taurine-conjugated bile salts more rapidly than glycine-conjugated bile salts .
PMID:16332456
Also transports non-bile acid compounds, such as pravastatin and fexofenadine in an ATP-dependent manner and may be involved in their biliary excretion PMID:15901796 PMID:18245269

ATC classification(2 codes)

ATC G01AE10

ATC C02KX01

Affected organisms(1)

Humans and other mammals

Salt forms(1)

Bosentan monohydrate(DBSALT001842)

Experimental properties(3)

External resources(2)

RxList Drugs.com

Protein Data Bank entries(1)

5xpr

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Bosentan

DB00559

CAS number

147536-97-8

UNII (FDA)

XUL93R30K2

InChI Key (molecular fingerprint)

GJPICJJJRGTNOD-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

12538

ChEBI

51450

PubChem Compound

104865

PubChem Substance

46507154

KEGG Drug

D01227

ChemSpider

94651

BindingDB

50061101

PharmGKB

PA10034

PDB

K86

Therapeutic Targets Database

DNC000341

Wikipedia

Bosentan

ChEMBL

CHEMBL957

ZINC

ZINC000001538857

RxCUI

75207

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3180

GenAtlas

EDNRB

GeneCards

EDNRB

GenBank Gene Database

M74921

GenBank Protein Database

182276

IUPHAR

220

Guide to Pharmacology

220

UniProtKB

P24530

UniProt Accession

EDNRB_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3179

GenAtlas

EDNRA

GeneCards

EDNRA

GenBank Gene Database

S63938

GenBank Protein Database

238636

IUPHAR

219

Guide to Pharmacology

219

UniProtKB

P25101

UniProt Accession

EDNRA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:42

GenAtlas

ABCB11

GeneCards

ABCB11

GenBank Gene Database

AF091582

GenBank Protein Database

3873243

Guide to Pharmacology

778

UniProtKB

O95342

UniProt Accession

ABCBB_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite:

DrugBank 6.02024Recommended citation
Knox C., Wilson M., Klinger C.M., et al
DrugBank 6.
0: the DrugBank Knowledgebase for 2024
Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
PMID: 37953279
DrugBank 5.02018
Wishart D.S., Feunang Y.D., Guo A.C., et al
DrugBank 5.
0: a major update to the DrugBank database for 2018
Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
PMID: 29126136
DrugBank 4.02014
Law V., Knox C., Djoumbou Y., et al
DrugBank 4.
0: shedding new light on drug metabolism
Nucleic Acids Res. 2014 Jan 142(1):D1091-7
PMID: 24203711
DrugBank 3.02011
Knox C., Law V., Jewison T., et al
DrugBank 3.
0: a comprehensive resource for 'omics' research on drugs
Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41
PMID: 21059682
DrugBank 2.02008
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a knowledgebase for drugs, drug actions and drug targets.
Nucleic Acids Research
2008 Jan36(Database issue):D901-6
PMID: 18048412
DrugBank 1.02006
Wishart D.S., Knox C., Guo A.C., et al
DrugBank: a comprehensive resource for in silico drug discovery and exploration.
Nucleic Acids Research
2006 Jan 134(Database issue):D668-72
PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 4 Mar 2026

Back to medicines

Bosentan 62.5mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

NICE clinical guidance(2)

Pharmacy stock checkers

Supply & safety information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science
5

Chemical identifiers

Bosentan

Additional database identifiers

DrugBank citations

Bosentan 62.5mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

NICE clinical guidance

NICE clinical guidance(2)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & safety information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

Research & evidence

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Volume of distribution

Metabolism

Elimination

Clearance

Clinical essentials

Pharmacology

Deep science5

Chemical identifiers

Bosentan

Additional database identifiers

DrugBank citations

Deep science
5